See also our related blogs for the Keller Laboratory and the Pediatric Preclinical Testing Initiative.

Thursday, July 21, 2011

NCI Provocative Questions Workshop

Today the NCI held one of its first "Provocative Questions" workshops off the NIH campus.  Moderated by Harvard faculty Dr. Ed Harlow, thought leaders in cancer research from Seattle and Portland discussed important and often unaddressed cancer biology questions for potential future focus of the National Cancer Institute.  The event was held at the Fred Hutchinson Cancer Center.  Pediatric Oncology was well represented!

Tuesday, July 19, 2011

The New

CureSearch for Children's Cancer recently launched their exciting and information-rich new website,  The website happens to feature exciting recent research at OHSU's Pediatric Cancer Biology Program.  OHSU is also proud to be the only COG/CureSearch Phase I Clinical Trials program in the state of Oregon, making the most newly developed cancer therapies available to the children in Portland, Southwest Washington and the state of Oregon.

Monday, July 18, 2011

Pediatric Hematology-Oncology Fellowship at OHSU

The Pediatric Hematology Oncology Fellowship program at OHSU is an exciting one with not only an outstanding clinical training experience, but  superb research training as well.  More information about this ACGME-accredited can be seen here, including a video about the childhood cancer program at OHSU Doernbecher Children's Hospital.  You can also contact program director, Dr. Michael Recht, rechtm (at) .   

Thursday, July 14, 2011

Sarcoma Conference in Kyoto

An international conference on sarcoma for surgeon-scientists has been organized this year by Dr. Junya Toguchida as the 44th Annual Musculoskeletal Tumor Meeting of the Japanese Orthopaedic Association.  The science presented by the Center for iPS Cell Research and Application (CiRA) and other Japanese centers and institutions has been outstanding.

A key point made during the conference from the Sarcoma Multi-Disciplinary Teams of the United Kingdom is that for best outcomes (and to prevent adverse outcomes) sarcoma care should be centralized to key care facilities with a dedicated team of orthopaedic oncologists, specialized sarcoma pathologists, sarcoma oncologists, radiation oncologists and patient support personnel (2 or greater for each subspecialty).  In Portland, OHSU is proud to be the only such team - and a particularly experienced one for pediatric sarcomas, and the only such program to integrate the most cutting-edge research and Phase I clinical trials made available to Oregon's sarcoma patients.